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INTRODUCTION
Ocular vascular diseases are among the leading 
causes of visual impairment (VI) and blindness 
worldwide.[1] Diabetic retinopathy (DR), diabetic macular 
edema (DME), age‑related macular degeneration (AMD), 
and retinal vein occlusion (RVO) are the most prevalent 
ocular vascular disorders. DR is an important cause of 
acquired vision loss among the world’s working‑age 
population.[2‑4] It is estimated that the number of people 
with DR and sight‑threatening DR will increase to 191 
million and 56.3 million, respectively by 2030.[5] In Iran, 
a population‑based study in Yazd province reported 
that DR accounted for 50% of blindness and 17% of 
VI.[6] AMD is also the main cause of severe VI among 
the elderly globally.[7,8] Due to the worldwide aging of 
the population, the global burden of AMD is expected 
to increase, affecting an estimated 196 million people in 
2020 and 288 million in 2040.[9]
In recent years, the introduction of vascular 
endothelial growth factor (VEGF) inhibitors (also 
known as anti‑VEGFs) has revolutionized the treatment 
of—and prognosis for—individuals with AMD, DME, 
and RVO.[10‑20] Anti‑VEGFs have an important role in 
treating common vision‑threatening retinal diseases 
and multiple studies have demonstrated the efficacy of 
intravitreal anti‑VEGF injection for management of these 
diseases.[21‑23] Thirty percent of patients with neovascular 
AMD reported an increase in visual acuity, and 90% 
reported preserved visual acuity following intravitreal 
anti‑VEGF injections.[13,24‑26] The off‑label anti‑VEGF 
drug (bevacizumab; Avastin®, Genentech/Roche), and 
US “Food and Drug Administration” approved anti‑VEGF 
agents including ranibizumab (Lucentis®;Genentech/
Novartis), and aflibercept (Eylea; Regeneron/Bayer)—
are used in Iran; however, the most common one is 
bevacizumab due to the lower cost and the insurance 
coverage. Although the safety and efficacy of these agents 
have been already reported, their rare complications can 
be devastating, leading to permanent visual loss.[21‑23,27,28] 
On the other hand, anti‑VEGF injections need to be 
repeated due to their short‑term efficacy.[29]
National clinical practice guidelines (CPGs) are 
developed to optimize the efficacy of interventions 
and to provide equity in access to treatment for 
all inhabitants of a country. CPGs contain clinical 
recommendations developed on the basis of high‑level 
available evidence that are adapted considering their 
efficacy, safety and cost of interventions, and the 
nation’s requirements. CPGs can help physicians and 
patients make appropriate decisions. They can also 
guide policymakers to improve the quality of care and 
reduce the costs.[30,31]
To the best of our knowledge, previously published 
protocols have specifically focused on intravitreal 
injection techniques, and there has been no CPG focused 
on the indications of anti‑VEGF agents for ocular 
vascular diseases. This CPG was developed under the 
supervision of the Office for Healthcare Standards, 
Deputy of Curative Affairs, Iran Ministry of Health and 
Medical Education to help choosing the appropriate 
anti‑VEGF agent and an appropriate interval for each 
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individual. Furthermore, the recommendations of 
this CPG will be useful for increasing the safety of the 
injections by providing specific recommendations. The 
recommendations in this CPG were also revised based 
on the customized criteria to help ophthalmologists make 
the best evidence‑based clinical decisions specifically 
applicable to Iran.
METHODS
This CPG for intravitreal injection of anti‑VEGF agents for 
the treatment of ocular vascular diseases was developed 
at the Knowledge Management Unit (KMU) at the 
Ophthalmic Research Center, Shahid Beheshti University 
of Medical Sciences, Tehran, Iran. The technical 
committee comprised the steering technical committee, 
eight retina specialists, three ophthalmologists, four 
Master of Science degree holders in optometry; and the 
head of the Office for Healthcare Standards and Deputy 
of Curative Affairs, Iran Ministry of Health and Medical 
Education.
Finding the Relevant Clinical Practice 
Guidelines
A large number of websites and databases such 
as Guidelines International Network, National 
Institute for Clinical Excellence, National Guidelines 
Clearinghouse, Scottish Intercollegiate Guidelines 
Network, New Zealand Guidelines Group, National 
Health and Medical Research Council, Cochrane, 
Bandolier, Canadian Agency for Drugs and Technologies 
in Health, Trip Database, PubMed, Google Scholar, SID, 
Medlib, and Magiran were searched to find the pertinent 
CPGs.
Screening the Extracted Clinical Practice 
Guidelines
Two protocols and CPGs, including “Guidelines 
for intravitreal injections procedure” (The Royal 
College of Ophthalmologists 2009) and “Intravitreal 
injection” (American Academy of Ophthalmology 2015) 
were extracted.[32,33] The researchers chose the reference 
guidelines using the Appraisal of Guidelines for Research 
and Evaluation (AGREE) tool.[34] These guidelines 
focused more on the intravitreal injection procedure.
Designing the Clinical Questions
Twenty clinical questions were designed by the technical 
committee. Two reference guidelines were reviewed to 
find the answers to the questions. The questions, along 
with the answers were extracted from the reference 
guidelines and were entered into Table 1.
Appraising and Summarizing Additional 
Evidence
Relevant  ar t i c les  were  excerpted  f rom the 
above‑mentioned databases to provide additional 
evidence to answer the clinical questions. These focused 
on indications of anti‑VEGF agents for treating ocular 
vascular diseases. The details of this evidence were 
summarized and entered into Table 2. The level of 
evidence was determined based on the parameters 
described in Table 3.
Providing Scenarios
The technical committee developed all scientifically 
possible answers (scenarios) based on the available 
evidence for each question and entered them into 
Tables 4 and 5.
External Review (Consensus)
All scenarios—along with Tables 1, 2, 4, and 5, and 
references—were sent to the retina specialists who were 
experts in this field. We requested them to review each 
question’s different scenarios and specify the best one 
by score. The score of 1 represented the worst and the 
score of 9 represented the best choice, considering the 
clinical benefits and customizing criteria.
Analyzing the Scores and Providing Final 
Recommendations
The level of agreement for each scenario was determined 
Table 1. Analysis of recommendations
Question P I 
(E)
C O Type of 
question
Referenced 
guidelines
Phrase of 
recommendation
Level of 
evidence
Inconsistency of 
recommendations
Technical 
breakthrough
New 
systematic 
review
New 
studies
This is the blank table template. P, patient or population; I, intervention; E, exposure; C, comparison; O, primary outcomes
Table 2. Analysis of evidences
Evidence code P I (E) C O Effect size Statistical values Level of evidence
This is the blank table template. P, patient or population; I, intervention; E, exposure; C, comparison; O, primary outcomes
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 EL: Consensus
2. Bilateral intravitreal injection is not recommended. 
However, it is not contraindicated and can be 
performed at the surgeon’s discretion. Separate 
gloves, surgical preps, and vials with different 
batches should be used for each eye.[41]
 EL: Consensus
3. The procedure can be conducted in the outpatient 
sterile operating room.
 EL: Consensus
4. Individual sterile gloves should be used for each 
patient.[41]
 EL: Consensus
5. Physicians should wear surgical masks when 
performing the injection. Physicians and patients 
should minimize speaking during the procedure.[41‑42]
6. The patient’s name, anti‑VEGF agent type, and 
laterality should be checked immediately before 
intravitreal injection.[41]
7. It is recommended that topical anesthetics be used before 
prep and drapes to minimize patient discomfort. [33,41]
8. Eyelids and the lid margins should be sterilized with 
povidone‑iodine (10%).[41]
9. The eyelids should be retracted from the intended 
injection site by a sterile spaculum and the needle 
should not have any touch with the lid margins.[41]
 EL: Consensus
10. Diluted povidine‑iodine (5%) should be applied to 
the conjunctival injection site for at least 30 seconds 
before injection.[41]
11. It is recommended that a 29 or 30 ‑gauge needle be 
used to perform anti‑VEGF intravitreal injections.[41]
 EL: Consensus
12. It is recommended that intravitreal injection be 
performed between the horizontal and vertical rectus 
muscles at the pars plana 3 and 4mm posterior to the 
limbus in pseudophakic and aphakic eyes, prospectively. 
However, the quadrant selection can be chosen using 
Table 5. Adaptability of the recommendations (external validity)[30]
Question P I C O Type 
of the 
question
Phrase of 
recommendation
Adaptability of the recommendation Adaptation score Total score
Applicability Acceptability Compatibility/
External 
validity
Low Low
Moderate Moderate
High High
This is the blank table template. P, patient or population; I, intervention; E, exposure; C, comparison; O, primary outcomes; Low: Score 1‑3; 
Moderate: Score 4‑6; High: Score 7‑10
according to the experts’ scores. The agreed‑upon 
scenario for each clinical question was considered as 
the final answer. If the experts did not agree on any 
of the scenarios of one clinical question, the technical 
committee made the necessary corrections by reviewing 
the evidences again. After that, we asked experts to score 
them again.
All confirmed scenarios were gathered as the final 
recommendations that were provided in the results along 
with their evidence levels (ELs).
RESULTS
G e n e r a l  R e c o m m e n d a t i o n s  a n d 
Recommendations for Intravitreal Anti-VEGF 
Injection Procedure
1. Anti‑VEGFs should be used cautiously in patients with 
a history of systemic vascular diseases such as stroke 
or myocardial infarction (MI) during the past three 
months. Appropriate consultations should be made 
before administration of anti‑VEGF injections.[35‑40]
Table 3. Level of evidence
Level of evidence Type of evidence
I Meta‑analysis
Systematic reviews
Randomized clinical trial
II Clinical trial
Well‑designed cohort
Well‑designed case control
Cross‑sectional
III Surveys
Descriptive
Case series 
IV Expert opinion, consensus
Table 4. Clinical benefit of the recommendations[30]
Question Phrase of 
recommendation
Level of 
evidence
Costs Clinical effectiveness of the 
recommendation
Clinical benefit score
Side effects Benefits Effect size Low Moderate High
This is the blank table template. P, patient or population; I, intervention; E, exposure; C, comparison; O, primary outcomes; Low: Score 1‑3; 
Moderate: Score 4‑6; High: Score 7‑10
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patient‑specific considerations and preference of 
the physician. In the majority of settings, a simple 
perpendicular injection approach is preferred.[41]
 EL: Consensus
13. It is not necessary to prescribe topical antibiotics 
immediately and/or for a few days after intravitreal 
injection. A growing body of evidence discourages 
the post‑injection antibiotics.[43‑48]
 EL: Consensus
14. It is recommended that intravitreal bevacizumab, 
aflibercept and ranibizumab be injected at a dosage of 
1.25 mg/0.05 ml, 2 mg/0.05 ml and 0.5 mg/0.05 ml, 
respectively in patients with ocular vascular diseases.[20,49]
15. An information brochure about the signs and 
symptoms of post‑injection complications and 
emergency contact details should be presented to 
patients after injection. Patients should be aware of 
the necessity of urgent visit in case of ocular pain 
and visual impairment. Therefore, a routine first day 
post‑injection visit is not necessary.
 EL: Consensus
16. In patients at risk for optic nerve damage due to the 
rise in intraocular pressure (IOP) after intravitreal 
injection, topical anti‑glaucoma drugs or anterior 
chamber paracentesis should be administered.[50]
 EL: Consensus
17. One of the following strategies can be used for 
injecting intravitreal anti‑VEGF agents based on the 
clinician’s priority:[51‑58]
a. Three consecutive monthly injections, followed 
by as‑needed injections (PRN)
b. Three consecutive monthly injections, followed 
by treatment intervals that will be sequentially 
lengthened by 2 weeks. However, the interval 
should not exceed 3 months (treat and extend)
c. One injection at first followed by PRN injections
       EL: Consensus
18. Although the rhegmatogenous retinal detachment (RRD) 
following intravitreal anti‑VEGF injections is 
rare (incidence = 0.013%), the risk of RRD should be 
considered, especially among myopic patients, who 
should be monitored after each injection.[45,59‑61]
 EL: II
Recommendations for Management of Retinal 
Vascular Diseases
Diabetic macular edema
General recommendations
1. All anti‑VEGF agents, including intravitreal 
ranibizumab (IVR), intravitreal bevacizumab (IVB), 
and intravitreal aflibercept are effective in 
inducing visual improvement and central macular 
thickness (CMT) reduction.[21,62,63]
 EL: I
2. Evidence showed that the 2‑year visual outcomes 
of IVB, IVR and aflibercept are the same in patients 
with baseline visual acuity of 20/40 or better. Among 
patients with baseline visual acuity of 20/50 or worse, 
intravitreal injection of aflibercept resulted in the 
best visual outcomes compared with bevacizumab 
and ranibizumab at 1‑year follow‑up. However, the 
superiority of aflibercept disappeared at year 2.[21]
 EL: I
3. According to the literature, short‑ and long‑term 
safety and efficacy of the IVB injection has been 
proved in DME patients.[64]
 EL: I
4. Intravitreal injection of bevacizumab is recommended 
as the first line treatment in patients with diabetes due 
to its effectiveness in reducing the VEGF level in the 
ocular media.[65‑67]
 EL: I
Indications
5. Periodic injection of IVB is recommended for patients 
with naive DME.[67‑81]
 EL: I
6. In patients with chronic DME, 5‑6 monthly injections 
of IVB are recommended.[82]
 EL: Consensus
7. IVB injection is recommended in patients with diffuse 
DME.[71,80,83, 84,85]
 EL: II
8. Three loading doses of IVB is recommended in 
patients with refractory DME.[86,87]
 EL: I
9. Patients with proliferative diabetic retinopathy (PDR) 
who have been scheduled for vitrectomy may receive 
intravitreal anti‑VEGF injection within one week 
before surgery to reduce intraoperative and early 
postoperative hemorrhage.[88]
 EL: I
10. Intravitreal injection of anti‑VEGF drugs may increase 
the risk of tractional retinal detachment in patients 
with extensive fibrovascular tissue. Therefore, it is 
recommended to perform the intravitreal injection 
3‑5 days before surgery in this subset of patients.[89‑96]
 EL: Consensus
11. Either panretinal photocoagulation (PRP) or the 
combination of IVB and PRP is recommended in 
patients with high risk PDR.[97‑101]
 EL: I
Comorbidities
12. DME should have been treated before cataract 
surgery. In addition, IVB may be injected 
intraoperatively.[102‑104]
 EL: I
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Neovascular age‑related macular degeneration
General recommendations
1. Considering the effectiveness, safety, and rare and 
transient complications of IVB and other anti‑VEGF 
drugs injections, it is recommended these drugs be 
used to treat patients with neovascular AMD.[62,105]
 EL: I
2. It is recommended that patients be given sufficient 
information regarding the need for repeated, frequent 
intravitreal anti‑VEGF injections for the treatment of 
neovascular AMD.[106]
 EL: III
3. Multiple intravitreal anti‑VEGF injections do not 
reduce retinal nerve fiber layer thickness. Therefore, 
it is recommended that intravitreal anti‑VEGF 
injections be repeated as needed.[107]
 EL: III
4. In unilateral anti‑VEGF injections, it is recommended 
that physicians consider the condition of the fellow 
eye.[108,109]
 EL: I
5. It is also recommended that IVB injection be used 
to treat patients with active neovascular AMD 
coexisting with retinal pigment epithelium (RPE) tear 
to improve their visual acuity.[110]
 EL: III
Risk factors
6. It is recommended that risk factors for poor visual 
acuity outcome—such as older age, larger choroidal 
neovascularization (CNV), and elevated pigment 
epithelial detachment (PED)—be considered before 
treating patients with neovascular AMD and inform 
them about the possibility of less favorable visual 
outcomes.[45,59‑61]
 EL: II
Complications
7. In patients with neovascular AMD who are 
undergoing anti‑VEGF treatment, there is a risk of 
scar formation especially in the cases of classic CNV, 
increased central retinal thickness, and the presence 
of excessive subfoveal fluids or deposits.[111]
 EL: II
8. To stabilize the visual and anatomic (CMT) 
outcomes in patients with persistent neovascular 
AMD (unresponsive to IVB), it is recommended 
that IVR or aflibercept injections be used. The 
presence of intraretinal fluid has an adverse 
effect on visual acuity improvement. However, 
residual subretinal fluid does not impede visual 
improvement and may even improve the visual 
acuity prognosis.[58,111,112]
 EL: I
Polypoidal choroidal vasculopathy
1. Combined photodynamic therapy and intravitreal 
anti‑VEGF injection is recommended for treatment of 
patient with polypoidal choroidal vasculopathy.[113,114]
 EL: I
Myopic choroidal neovascularization
General recommendations
1. It is recommended that intravitreal anti‑VEGF drugs 
be used in patients with myopic CNV to improve the 
vision and to reduce CMT.[115,116]
 EL: I
2. In patients with myopic CNV, it is recommended 
that IVB be injected first, and photodynamic 
therapy (PDT) should then be performed in cases 
resistant to the treatment. [115‑117]
 EL: I
Risk factors
3. Vision improvement following anti‑VEGF intravitreal 
injections was higher in patients with myopic CNV 
who were aged less than 50 years. Therefore, it is 
recommended that funduscopy be performed in 
young patients with high degrees of myopia to ensure 
early detection and timely treatment of CNV.[118]
 EL: III
4. Older patients with high degrees of myopia and 
subfoveal CNV, and/or those with higher levels of 
myopia, and/or those with primary extensive CNV, 
hemorrhage, and choroidal thickness reduction 
are at risk of CNV recurrence after IVB treatment. 
Therefore, it is recommended that they undergo 
periodic examinations at appropriate intervals.[119,120]
 EL: III
Other types of choroidal neovascularization
5. Due to the effectiveness and safety of intravitreal 
anti‑VEGF injection in pediatric patients with CNV, 
it is recommended that these drugs be used for 
pediatric’s CNV.[121]
 EL: III
6. It is recommended that IVB injections be used for 
patients with idiopathic subfoveal CNV or cases with 
previous inflammation.[115,116,122‑124]
 EL: I
Branch retinal vein occlusion
General recommendations
1. IVB is more effective in terms of visual acuity 
improvement and CMT reduction compared with 
the other treatment modalities (IVT, laser) for treating 
branch retinal vein occlusion (BRVO). Therefore, IVB 
injection is recommended for patients with macular 
edema secondary to BRVO.[125‑130]
 EL: I
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2. Since IVB or IVR injection has long‑term effects on 
visual acuity improvement in patients with perfused 
BRVO, it is recommended that these agents be 
injected in patients with macular edema secondary 
to perfused BRVO.[131]
 EL: I
3. Better therapeutic effects can be achieved in patients 
with macular edema due to BRVO after early 
treatment (within two weeks after the diagnosis). 
Therefore, it is recommended that IVB be injected in 
these patients early after diagnosis.[132]
 EL: III
Procedure
4. In patients with macular edema due to BRVO, four IVB 
injections within 6 months are recommended.[133‑138]
 EL: I
Risk factors
5. Lower baseline visual acuity, older age, longer 
duration, and non‑perfused BRVO are risk factors 
for visual improvement after IVB injection. Hence, it 
is recommended that these risk factors be considered 
and that patients be informed before injections.[139]
 EL: III
6. IVB in BRVO patients with vitreomacular 
adhesion (VMA) leads to better visual and anatomical 
outcomes (more CMT reduction). Therefore, VMA is 
not considered as a risk factor in this regard.[140]
 EL: III
Central retinal vein occlusion
General recommendations
1. Anti‑VEGF intravitreal injection is an effective and 
safe treatment for macular edema secondary to central 
retinal vein occlusion (CRVO) for up to 2 years; delayed 
treatment would lead to poor visual outcome.[132]
 EL: III
2. Despite acceptable short‑term visual outcomes 
after intravitreal steroid injection and intraocular 
steroid implants in patients with CRVO, possible 
side effects include cataract formation and increased 
IOP. Therefore, anti‑VEGF agents are the preferred 
treatment in these cases.[141‑148]
 EL: I
Procedure
3. In patients with macular edema secondary to 
CRVO, eight IVB injections within 12 months are 
recommended.[133‑138]
 EL: I
Risk factors
4. In patients with CRVO who have disruption of the 
external limiting membrane (ELM), IVB or IVR 
injection is associated with reduced visual acuity 
improvement. Therefore, it is recommended that the 
integrity of the ELM be evaluated before treatment 
to determine the prognosis for visual outcomes.[149]
 EL: III
Central serous chorioretinopathy
1. The use of anti‑VEGF intravitreal injections for treating 
eyes with central serous chorioretinopathy (CSC) 
remains controversial. Therefore, recommendations 
regarding intravitreal anti‑VEGF injections for the 
treatment of CSC are summarized as follows:[150‑154]
•	 It is recommended that patients with acute CSC 
only be followed up
•	 In patients with chronic CSC, half‑dose 
photodynamic therapy is recommended
 EL: I
DISCUSSION
Anti‑VEGF agents have changed the treatment pattern 
for ocular vascular diseases.[1] The importance of 
timely treatment of the diseases previously described 
through the use of VEGF inhibitors for preventing 
vision loss[3] and the lack of CPGs for defining proper 
indication of these agents encouraged us to develop such 
CPG.[3] Development of CPGs for intravitreal injection 
of anti‑VEGF agents in ocular vascular diseases was 
undertaken at KMU, Ophthalmic Research Center, 
Shahid Beheshti University of Medical Sciences, Tehran, 
Iran, in collaboration with the Ministry of Health and 
Medical Education.
This guideline includes 56 recommendations for the 
indication and management of DME, neovascular AMD, 
myopic CNV, RVO, and CSC using anti‑VEGF agents.
Providing multiple scenarios for each clinical question 
was the strength of our research. In this approach, we 
presented different treatment modalities based on 
available evidence and asked experts to choose the best 
treatment strategy considering clinical and individual 
criteria. Therefore, we could evaluate their agreement 
on answers to each clinical question more accurately.
Experts agreed on at least one of the scenarios for 
each clinical question. Thirteen questions had more 
than one agreed‑upon scenarios. These questions, 
along with their scenarios, were reviewed again by the 
technical committee to select the best scenario as the final 
recommendation.
The role of anti‑VEGF agents in treatment of CSC has 
remained controversial and there is limited high‑level 
evidence for managing this condition. Although a 
number of scenarios were developed in this regard, 
most of them were refused by experts in the external 
review process. Future multicenter research is needed 
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to determine the effect of anti‑VEGF agents in patients 
with CSC.
In conclusion, the CPG for intravitreal injection of 
anti‑VEGFs for ocular vascular diseases was developed 
using existing high‑level evidence to improve the equity 
in access to the best available evidence‑based treatments 
for all society members. At the national level, this work 
complies with the strategic objective of the Ministry of 
Health and Medical Education. This objective includes 
developing, adapting, and implementing the CPGs and 
extending healthcare services.
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